Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target effects shaping long-term outcomes. For this reason...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelke, Christopher, Schroeter, Christina B., Stascheit, Frauke, Huntemann, Niklas, Pawlitzki, Marc, Willison, Alice, Räuber, Saskia, Melzer, Nico, Distler, Ute, Tenzer, Stefan, Stühler, Kai, Roos, Andreas, Meisel, Andreas, Meuth, Sven G., Ruck, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371336/
https://www.ncbi.nlm.nih.gov/pubmed/37227781
http://dx.doi.org/10.1172/jci.insight.169135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371336/
https://www.ncbi.nlm.nih.gov/pubmed/37227781
http://dx.doi.org/10.1172/jci.insight.169135

Ejemplares similares